{
    "Clinical Trial ID": "NCT00300781",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Neratinib 240, Prior Trastuzumab",
        "  Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment.",
        "INTERVENTION 2: ",
        "  Neratinib 240, No Prior Trastuzumab",
        "  Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Pathologic diagnosis of breast cancer and current stage IIIB, IIIC, or IV",
        "  Progression following at least 6 weeks of standard doses of Herceptin (Arm A only)",
        "  Over-expression of HER2",
        "  Tumor tissue available and adequate for analysis at screening",
        "  At least one measurable lesion",
        "Exclusion Criteria:",
        "  Prior treatment with Herceptin (Arm B only)",
        "  More than 4 prior cytotoxic chemotherapy regimens",
        "  Subjects with bone or skin as the only site of measurable disease",
        "  Inadequate cardiac function",
        "  Major surgery, chemotherapy, radiotherapy, investigational agents or other cancer therapy within 1 week of treatment day 1",
        "  Active central nervous system metastases",
        "  Pregnant or breastfeeding women",
        "  Inability to swallow the HKI-272 capsules"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  16-week Progression Free Survival",
        "  16 week progression-free survival (PFS) rate of neratinib in women with human epidermal growth factor receptor 2 (HER2) positive breast cancer, either with prior trastuzumab or no prior trastuzumab therapy, evaluated by independent assessment of tumor scans collected at baseline and then every 8 weeks.",
        "  Time frame: From first dose to 16 weeks",
        "Results 1: ",
        "  Arm/Group Title: Neratinib 240, Prior Trastuzumab",
        "  Arm/Group Description: Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment.",
        "  Overall Number of Participants Analyzed: 66",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  58.2        (45.3 to 71.2)",
        "Results 2: ",
        "  Arm/Group Title: Neratinib 240, No Prior Trastuzumab",
        "  Arm/Group Description: Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment.",
        "  Overall Number of Participants Analyzed: 70",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  77.8        (67.6 to 88.1)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 19/66 (28.79%)",
        "  Anaemia 0/66 (0.00%)",
        "  Atrioventricular block 0/66 (0.00%)",
        "  Bradycardia 0/66 (0.00%)",
        "  Diarrhoea 4/66 (6.06%)",
        "  Nausea 2/66 (3.03%)",
        "  Vomiting 3/66 (4.55%)",
        "  Asthenia 0/66 (0.00%)",
        "  Fatigue 1/66 (1.52%)",
        "  Malaise 0/66 (0.00%)",
        "  Pyrexia 0/66 (0.00%)",
        "  Disseminated tuberculosis 0/66 (0.00%)",
        "  Folliculitis 0/66 (0.00%)",
        "  Hepatitis E 0/66 (0.00%)",
        "Adverse Events 2:",
        "  Total: 17/70 (24.29%)",
        "  Anaemia 1/70 (1.43%)",
        "  Atrioventricular block 1/70 (1.43%)",
        "  Bradycardia 1/70 (1.43%)",
        "  Diarrhoea 4/70 (5.71%)",
        "  Nausea 0/70 (0.00%)",
        "  Vomiting 6/70 (8.57%)",
        "  Asthenia 1/70 (1.43%)",
        "  Fatigue 0/70 (0.00%)",
        "  Malaise 1/70 (1.43%)",
        "  Pyrexia 1/70 (1.43%)",
        "  Disseminated tuberculosis 1/70 (1.43%)",
        "  Folliculitis 1/70 (1.43%)",
        "  Hepatitis E 1/70 (1.43%)"
    ]
}